JPRN-UMIN000008909已完成未知
Effects of febuxostat on serum uric acid and arteriosclerosis in allopurinol-treated hyperuricemia patients with chronic kidney disease - Effects of febuxostat on arteriosclerosis in hyperuricemia patients with CKD
Department of Nephrology and Hypertension, Kawasaki Medical School0 个研究点目标入组 50 人开始时间: 2012年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients treated by febuxostat currently or within 24 weeks before checking the eligibility 2) Patients with past hypersensitivity to febuxostat 3) Past histories of gout or urolithiasis within 24 weeks before checking the eligibility 4) Patients with diabetes controlled insufficiently (HbA1c level is more than 8.4%) 5) Patients whose systolic or diastolic blood pressure show more than 160mmHg or more than 100mmHg, respectively 6) Patients whose AST or ALT show twice more than the upper limit of reference values 7) Past hospitalization within 24 weeks before checking the eligibility 8) Patients with current or past malignant tumor However, patients who have not been treated for malignant tumor within 5 years before checking the eligibility and show no recurrence when checking the eligibility are not excluded. 9) Patients with severe cardiovascular diseases 10) Patients currently treated for inflammatory or consumptive diseases 11) Patients currently treated for acute renal failure, active nephritis or nephrotic syndrome 12) Patients treated by steroids or immunosuppressive agents 13) Patients treated by one of the below drugs when checking the eligibility Mercaptopurine hydrate, azathioprine, vidarabine, didanosine 14) Patients with administration, dose change or discontinuance of one of the below drugs within 4 weeks before checking the eligibility Losartan, fenofibrate, thiazide or loop diuretic 15) Patients currently treated by salicylate drugs However, patients treated by low-dose aspirin (less than 324mg/day) are not excluded. 16) Patients with hormone replacement therapy by estrogen 17) Patients who have participated in the other clinical study (trial) within 24 weeks before checking the eligibility 18) Female in current or expected pregnancy 19) Patients judged as unsuitable for participating in this study by the attending physician
研究者
相似试验
已完成
不适用
Effect of febuxostat on serum uric acid and renal function in patients with hyperuricemia. -open label, active (allopurinol)-controlled clinical studyHyperuricemiaJPRN-UMIN000008727Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine100
已完成
4 期
Effect of febuxisostat on serum uric acid levels and endothelial function in patients with hyperuricemiaHyperuricemiaJPRN-UMIN000008753Department of Cardiovascular Medicine, Juntendo University School of Medicine10
招募中
不适用
effects of Uric-acid-lowering agent, FebuxOstat on subclinical inflammation in patients with hyperuricemia (UFO study)hyperuricemiaJPRN-UMIN000009262FO study Investigators100
已完成
不适用
Effect of febuxostat on vascular endothelial function in patients with hyperuricemiahyperuricemiaJPRN-UMIN000008900Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University60
尚未招募
不适用
the effect of febuxostat on vascular endothelial function in subjects with hyperuricemia and ischemic heart diseasehyperuricemia and ischemic heart diseaseJPRN-UMIN000012342ational Cerebral and Cardiovascular Center.62